Literature DB >> 16816213

Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?

Gary Remington.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16816213     DOI： 10.1176/ajp.2006.163.7.1132

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   19.242


× No keyword cloud information.
  8 in total

1.  Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.

Authors:  Chian-Jue Kuo; Shu-Yu Yang; Ya-Tang Liao; Wei J Chen; Wen-Chung Lee; Wen-Yi Shau; Yao-Tung Chang; Shang-Ying Tsai; Chiao-Chicy Chen
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

Review 2.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

3.  Metabolic issues in schizophrenic patients receiving antipsychotic treatment.

Authors:  Aditi Gupta; Gora Dadheech; Dharamveer Yadav; Praveen Sharma; Shiv Gautam
Journal:  Indian J Clin Biochem       Date:  2014-01-23

Review 4.  An Overview of Links Between Obesity and Mental Health.

Authors:  Christian Avila; Alison C Holloway; Margaret K Hahn; Katherine M Morrison; Maria Restivo; Rebecca Anglin; Valerie H Taylor
Journal:  Curr Obes Rep       Date:  2015-09

5.  The iHOPE-20 study: mortality in first episode psychosis-a 20-year follow-up of the Dublin first episode cohort.

Authors:  Roisin Doyle; Donal O'Keeffe; Ailish Hannigan; Anthony Kinsella; Caragh Behan; Aine Kelly; Ann Sheridan; Kevin Madigan; Elizabeth Lawlor; Mary Clarke
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-05-09       Impact factor: 4.328

6.  Mortality in schizophrenia and other psychoses: a 10-year follow-up of the ӔSOP first-episode cohort.

Authors:  Ulrich Reininghaus; Rina Dutta; Paola Dazzan; Gillian A Doody; Paul Fearon; Julia Lappin; Margaret Heslin; Adanna Onyejiaka; Kim Donoghue; Ben Lomas; James B Kirkbride; Robin M Murray; Tim Croudace; Craig Morgan; Peter B Jones
Journal:  Schizophr Bull       Date:  2014-09-27       Impact factor: 9.306

7.  THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE.

Authors:  L Dehelean; A M Romosan; M M Manea; I Papava; M Andor; R S Romosan
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jul-Sep       Impact factor: 0.877

8.  A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication.

Authors:  Minodora Andor; Liana Dehelean; Ana-Maria Romosan; Valentina Buda; Gabriela Radu; Florina Caruntu; Aurora Bordejevic; Minodora Marinela Manea; Ion Papava; Cristina Ana Bredicean; Radu Stefan Romosan; Mirela Tomescu
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-25       Impact factor: 2.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.